157 related articles for article (PubMed ID: 27312193)
1. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
Caulet M; Lecomte T; Bouché O; Rollin J; Gouilleux-Gruart V; Azzopardi N; Léger J; Borg C; Douillard JY; Manfredi S; Smith D; Capitain O; Ferru A; Moussata D; Terrebone E; Paintaud G; Ternant D
Clin Pharmacokinet; 2016 Nov; 55(11):1381-1394. PubMed ID: 27312193
[TBL] [Abstract][Full Text] [Related]
2. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
Papachristos A; Karatza E; Kalofonos H; Sivolapenko G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466535
[TBL] [Abstract][Full Text] [Related]
4. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
[TBL] [Abstract][Full Text] [Related]
5. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
8. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
9. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
10. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
11. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.
Panoilia E; Schindler E; Samantas E; Aravantinos G; Kalofonos HP; Christodoulou C; Patrinos GP; Friberg LE; Sivolapenko G
Cancer Chemother Pharmacol; 2015 Apr; 75(4):791-803. PubMed ID: 25687989
[TBL] [Abstract][Full Text] [Related]
13. Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer.
Peña-Cabia S; Royuela Vicente A; Ramos Díaz R; Gutiérrez Nicolás F; Peñalver Vera Á; Siso García I; Hitt Sabag R; García Lacalle C; Peña-Cabia A; Iglesias-Peinado I; García Díaz B; López-Martín A
Biomed Pharmacother; 2021 Sep; 141():111827. PubMed ID: 34153845
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
16. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
17. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
[TBL] [Abstract][Full Text] [Related]
18. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
[TBL] [Abstract][Full Text] [Related]
19. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
[TBL] [Abstract][Full Text] [Related]
20. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer.
Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A
Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
